Pop Mart International Group (OTCMKTS:PMRTY) Shares Gap Up – Here’s What Happened
by Kim Johansen · The Markets DailyPop Mart International Group Limited – Unsponsored ADR (OTCMKTS:PMRTY – Get Free Report)’s stock price gapped up prior to trading on Friday. The stock had previously closed at $16.46, but opened at $17.44. Pop Mart International Group shares last traded at $16.74, with a volume of 10,119 shares trading hands.
Wall Street Analyst Weigh In
Several research firms recently weighed in on PMRTY. Zacks Research raised Pop Mart International Group from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group cut Pop Mart International Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 21st. Two research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the company has an average rating of “Hold”.
Read Our Latest Stock Report on PMRTY
Pop Mart International Group Price Performance
The company’s 50-day moving average price is $19.19 and its 200-day moving average price is $20.02.
Pop Mart International Group Company Profile
Pop Mart International Group Ltd. is a China-based company that designs, develops and sells collectible designer toys and related consumer products. Its offerings include blind-box figures, plush toys, art toys, accessories, stationery and other merchandise built around original and licensed intellectual properties.
The company’s portfolio includes popular character lines such as The Monsters, Molly, Skullpanda, Dimoo, Crybaby, Hirono and Pucky. Pop Mart distributes its products through physical retail stores, automated vending machines, online platforms and other direct-to-consumer channels.
See Also
- Five stocks we like better than Pop Mart International Group
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
- Capital One Earnings: After a Double Beat the Rally Is On
- Tractor Supply’s Q3 Beat Plants the Seeds for a Stock Rebound
- WD-40 Could Reward Patient Investors—Here’s Why